Bank of New York Mellon’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.36M | Buy |
568,706
+541,247
| +1,971% | +$1.05M | ﹤0.01% | 3180 |
|
|
2026
Q1 | $42.8K | Buy |
27,459
+8,335
| +44% | +$12.1K | ﹤0.01% | 4148 |
|
|
2025
Q4 | $22K | Hold |
19,124
| – | – | ﹤0.01% | 4165 |
|
|
2025
Q3 | $25.8K | Hold |
19,124
| – | – | ﹤0.01% | 4156 |
|
|
2025
Q2 | $18.1K | Sell |
19,124
-290,995
| -94% | -$189K | ﹤0.01% | 4117 |
|
|
2025
Q1 | $143K | Sell |
310,119
-4,800
| -2% | -$3.03K | ﹤0.01% | 3956 |
|
|
2024
Q4 | $233K | Buy |
314,919
+139
| +0% | +$168 | ﹤0.01% | 3898 |
|
|
2024
Q3 | $494K | Sell |
314,780
-87,128
| -22% | -$155K | ﹤0.01% | 3525 |
|
|
2024
Q2 | $675K | Buy |
401,908
+109,902
| +38% | +$197K | ﹤0.01% | 3405 |
|
|
2024
Q1 | $701K | Sell |
292,006
-49,071
| -14% | -$105K | ﹤0.01% | 3332 |
|
|
2023
Q4 | $522K | Buy |
341,077
+9,754
| +3% | +$11.6K | ﹤0.01% | 3527 |
|
|
2023
Q3 | $361K | Sell |
331,323
-6,352
| -2% | -$11.1K | ﹤0.01% | 3722 |
|
|
2023
Q2 | $773K | Buy |
337,675
+20,173
| +6% | +$53.5K | ﹤0.01% | 3358 |
|
|
2023
Q1 | $772K | Sell |
317,502
-8,516
| -3% | -$19.5K | ﹤0.01% | 3254 |
|
|
2022
Q4 | $623K | Buy |
326,018
+34,358
| +12% | +$73.1K | ﹤0.01% | 3440 |
|
|
2022
Q3 | $699K | Buy |
291,660
+34,564
| +13% | +$95.7K | ﹤0.01% | 3385 |
|
|
2022
Q2 | $478K | Sell |
257,096
-27,514
| -10% | -$52.5K | ﹤0.01% | 3626 |
|
|
2022
Q1 | $595K | Buy |
284,610
+362
| +0.1% | +$1K | ﹤0.01% | 3610 |
|
|
2021
Q4 | $1.12M | Buy |
284,248
+23,258
| +9% | +$113K | ﹤0.01% | 3320 |
|
|
2021
Q3 | $1.25M | Buy |
260,990
+19,655
| +8% | +$80.7K | ﹤0.01% | 3272 |
|
|
2021
Q2 | $1.11M | Buy |
241,335
+39,919
| +20% | +$192K | ﹤0.01% | 3345 |
|
|
2021
Q1 | $1.18M | Buy |
201,416
+13,821
| +7% | +$95.7K | ﹤0.01% | 3243 |
|
|
2020
Q4 | $641K | Sell |
187,595
-321,671
| -63% | -$614K | ﹤0.01% | 3487 |
|
|
2020
Q3 | $733K | Sell |
509,266
-62,085
| -11% | -$111K | ﹤0.01% | 3299 |
|
|
2020
Q2 | $1.14M | Sell |
571,351
-174,914
| -23% | -$343K | ﹤0.01% | 3032 |
|
|
2020
Q1 | $1.46M | Sell |
746,265
-48,611
| -6% | -$145K | ﹤0.01% | 2722 |
|
|
2019
Q4 | $3.3M | Buy |
794,876
+609,611
| +329% | +$2.35M | ﹤0.01% | 2550 |
|
|
2019
Q3 | $557K | Sell |
185,265
-5,624
| -3% | -$17.4K | ﹤0.01% | 3473 |
|
|
2019
Q2 | $1.2M | Sell |
190,889
-5,312
| -3% | -$31.8K | ﹤0.01% | 3094 |
|
|
2019
Q1 | $1.09M | Buy |
196,201
+8,798
| +5% | +$53.4K | ﹤0.01% | 3114 |
|
|
2018
Q4 | $1.24M | Sell |
187,403
-1,336
| -0.7% | -$10.8K | ﹤0.01% | 2990 |
|
|
2018
Q3 | $2.01M | Sell |
188,739
-7,471
| -4% | -$85.6K | ﹤0.01% | 2832 |
|
|
2018
Q2 | $2.35M | Sell |
196,210
-7,617
| -4% | -$77.9K | ﹤0.01% | 2766 |
|
|
2018
Q1 | $1.75M | Buy |
203,827
+3,579
| +2% | +$33.1K | ﹤0.01% | 2884 |
|
|
2017
Q4 | $1.98M | Sell |
200,248
-2,869
| -1% | -$29.8K | ﹤0.01% | 2845 |
|
|
2017
Q3 | $2.5M | Sell |
203,117
-52,755
| -21% | -$779K | ﹤0.01% | 2713 |
|
|
2017
Q2 | $4.21M | Sell |
255,872
-24,381
| -9% | -$378K | ﹤0.01% | 2409 |
|
|
2017
Q1 | $4.02M | Buy |
280,253
+19,176
| +7% | +$285K | ﹤0.01% | 2434 |
|
|
2016
Q4 | $3.61M | Buy |
261,077
+20,155
| +8% | +$323K | ﹤0.01% | 2505 |
|
|
2016
Q3 | $4.35M | Buy |
240,922
+46,756
| +24% | +$752K | ﹤0.01% | 2300 |
|
|
2016
Q2 | $2.79M | Sell |
194,166
-2,098
| -1% | -$28.5K | ﹤0.01% | 2521 |
|
|
2016
Q1 | $2.35M | Sell |
196,264
-4,686
| -2% | -$49.1K | ﹤0.01% | 2570 |
|
|
2015
Q4 | $2.67M | Sell |
200,950
-1,039
| -0.5% | -$12.8K | ﹤0.01% | 2542 |
|
|
2015
Q3 | $2.17M | Sell |
201,989
-27,858
| -12% | -$304K | ﹤0.01% | 2689 |
|
|
2015
Q2 | $1.85M | Buy |
229,847
+17,601
| +8% | +$129K | ﹤0.01% | 2973 |
|
|
2015
Q1 | $1.4M | Buy |
212,246
+24,142
| +13% | +$165K | ﹤0.01% | 3095 |
|
|
2014
Q4 | $1.2M | Sell |
188,104
-2,617
| -1% | -$21.1K | ﹤0.01% | 3190 |
|
|
2014
Q3 | $1.88M | Buy |
190,721
+15,679
| +9% | +$167K | ﹤0.01% | 2926 |
|
|
2014
Q2 | $1.97M | Sell |
175,042
-8,571
| -5% | -$92.1K | ﹤0.01% | 2906 |
|
|
2014
Q1 | $2.22M | Sell |
183,613
-16,970
| -8% | -$217K | ﹤0.01% | 2813 |
|
|
2013
Q4 | $2.53M | Sell |
200,583
-1,002
| -0.5% | -$15.9K | ﹤0.01% | 2742 |
|
|
2013
Q3 | $3.36M | Sell |
201,585
-21,221
| -10% | -$356K | ﹤0.01% | 2491 |
|
|
2013
Q2 | $3.38M | Buy |
+222,806
| New | +$3.39M | ﹤0.01% | 2426 |
|
Other funds holding LXRX
N
CLOS
GCP
Bank of New York Mellon's LXRX Position: Q2 2026 in Review
Bank of New York Mellon increased its Lexicon Pharmaceuticals (LXRX) stake by 1,971% in Q2 2026, buying an estimated $1.05M and bringing the position to 568,706 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3180.
Bank of New York Mellon first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.35M in Q3 2016. 79 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.
- Bank of New York Mellon held 568,706 shares of Lexicon Pharmaceuticals worth $1.36M as of Q2 2026.
- Bank of New York Mellon bought 541,247 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
- Lexicon Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3180 holding.
- Bank of New York Mellon first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Lexicon Pharmaceuticals position peaked at $4.35M in Q3 2016.
- 79 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.